Editors at the journal Nature Medicine recently asked researchers and public health experts from around the world to identify clinical trials that will shape medicine in 2023. They came up with a varied list of candidates, from cervical and prostate cancer screening protocols to gene therapy for muscular dystrophy and new drugs for Parkinson’s disease and Alzheimer’s disease. The selections are arbitrary and idiosyncratic, but they are interesting, nevertheless.
When last I looked, J&J had $325 million in judgments against them in lawsuits over talc baby powder and its presumed role as a cause of ovarian cancer in several women. Even the International Agency for Research on Cancer, the people that believe hot beverages are probably carcinogenic, "… has since concluded there is only 'possible' evidence that perineal use of talc-based body powder may be carcinogenic." A new study in JAMA looks at four cohort studies with long-term information on talc use and subsequent self-reported ovarian cancer. It seems that possible may be too strong; they found no linkage.
In the spirit of Breast Cancer awareness month and promoting women’s health, we are excited to have had Dr. Susan Wolf in our Manhattan office today for our Making the Rounds Facebook Live video streaming series. Dr. Wolf is a Reproductive Endocrinologist specializing in infertility and menopause. Additionally, she is a breast cancer and melanoma survivor - and, “borderline ovarian” which she personally addressed in our discussion. Watch the session now!
Ovarian cancer is the most deadly cancer of the female reproductive tract — at least partly because it is not found until it has progressed. New research on mouse models of the disease suggests that there may be a way to halt that progression — by disinhibiting the body's immune system and allowing it to attack the tumor(s).
Medical practitioners and patients live in “a sea of uncertainty, where the stressful unknown drives us “to seek more information through testing” to increase our certainty. But more data is not necessarily helpful, according to an online report in JAMA Oncology examining the impact of evidence-based recommendations on physician behavior.
Personalized medicine is the rage but it's yet to realize much of its potential. That is why a study that was recently reported for ovarian cancer surveillance is exciting.
A South Korean court ruled that a plant worker's death from ovarian cancer can be causally attributed to exposure from the "carcinogens" formaldehyde and phenol. But there is no evidence that phenol is a carcinogen, and her duration and level of exposure are also not realistic causes of her fatal illness.
Ovarian cancer is the leading cause of death in the U.S. from a gynecological malignancy. A recent study of the disease, the third and largest randomized, controlled trial ever with up to a 15-year follow-up, shows that screening for this type of cancer improves mortality rates by an estimated 20 percent.
In today's "you never know what is around the corner" department, a surprising story says that beta-blockers heart drugs that are used to lower blood pressure and slow the heart may have another use. That would be reducing the toll of ovarian cancer, which is one of the hardest types to treat.
A new study of combination intra-abdominal and intravenous chemotherapy for advanced ovarian cancer confirmed its significant benefits in terms of survival. So why aren t more Stage III and IV cancer patients getting this effective therapy? A combination of ignorance and greed seems likely.
The American College of Physicians has come out with a report that questions the value of current screening recommendations and protocols. The report, released yesterday in the Annals of Internal Medicine, calls into question whether current screening practices exhibit high
In 2015, an estimated 21,000 American women will be diagnosed with ovarian cancer and over 14,000 women will die from the disease. Ovarian cancer ranks fifth in cancer deaths